US 11,938,226 B2
Abiotic anti-VEGF nanoparticle
Kenneth J. Shea, Irvine, CA (US); Hiroyuki Koide, Shizuoka (JP); Yoshiko Miura, Fukuoka (JP); Yu Hoshino, Fukuoka (JP); Yuri Nishimura, Fukuoka (JP); and Naoto Oku, Shizuoka (JP)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); Yoshiko Miura, Fukuoka (JP); Yu Hoshino, Fukuoka (JP); Yuri Nishimura, Fukuoka (JP); and Naoto Oku, Shizuoka (JP)
Filed on Sep. 23, 2022, as Appl. No. 17/934,727.
Application 17/934,727 is a continuation of application No. 16/327,898, granted, now 11,458,107, previously published as PCT/US2017/048528, filed on Aug. 25, 2017.
Claims priority of provisional application 62/379,584, filed on Aug. 25, 2016.
Prior Publication US 2023/0029277 A1, Jan. 26, 2023
Int. Cl. A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61K 31/704 (2006.01); A61K 31/785 (2006.01); A61K 31/795 (2006.01); A61K 35/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 9/5146 (2013.01) [A61K 9/0019 (2013.01); A61K 31/704 (2013.01); A61K 31/785 (2013.01); A61K 31/795 (2013.01); A61P 35/00 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A method of inhibiting angiogenesis in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and an abiotic, synthetic cross-linked polymer having affinity to vascular endothelial growth factor (VEGF), comprising:
N-isopropylacrylamide (NIPAm);
N-tert-butylacrylamide (TBAm);
N,N′-methylenebisacrylamide (Bis); and
a sulfated N-acetylglucosamine (GlcNAc), wherein the polymer comprises between 1% and 3% sulfated GlcNAc.